AMC MCQ (CAT) respiratory medicine questions

For low-severity community-acquired pneumonia managed in the community without comorbidities or penicillin allergy, Therapeutic Guidelines recommend amoxicillin as first-line empirical therapy because Streptococcus pneumoniae remains the most common causative organism and amoxicillin provides reliable coverage with a narrow spectrum. Doxycycline is reserved as an alternative for penicillin allergy or when atypical pathogens are suspected. Cefalexin has inferior pneumococcal activity compared with amoxicillin and is not preferred first line. Fluoroquinolones and trimethoprim-sulfamethoxazole are not recommended due to resistance concerns, side-effect profile and lack of reliable pneumococcal coverage respectively.

• B. Cefalexin has less reliable activity against Streptococcus pneumoniae than amoxicillin and is not first-line for CAP.
• C. Trimethoprim-sulfamethoxazole does not reliably cover Streptococcus pneumoniae and is not used for CAP.
• D. Fluoroquinolones are not recommended as first-line therapy for low-severity CAP due to resistance concerns and toxicity.
• E. Doxycycline is an alternative for penicillin-allergic patients or when atypical pathogens are suspected, not first line here.

The combination of young age, subacute dry cough, headache, extrapulmonary features such as rash, a clustered outbreak among close contacts, and chest X-ray changes disproportionate to clinical signs is classic for Mycoplasma pneumoniae infection. Mycoplasma commonly causes outbreaks in settings of close contact such as shared housing, schools or military barracks. Unlike typical bacterial pneumonia, it often presents with minimal auscultatory findings despite significant radiographic infiltrates. Streptococcus pneumoniae typically causes a more acute, lobar pneumonia with high fever and productive cough. Legionella is associated with exposure to contaminated water sources and a more severe, multisystem illness.

• A. Legionella typically follows exposure to contaminated water systems and causes a more severe illness with gastrointestinal and neurological features.
• B. Haemophilus influenzae typically affects patients with underlying lung disease and does not classically cause outbreaks with rash.
• C. Streptococcus pneumoniae typically causes an acute lobar pneumonia with high fever and productive cough, not this subacute pattern with rash.
• D. Staphylococcus aureus pneumonia typically follows influenza infection or occurs in intravenous drug users, with a more fulminant course.

This patient has clinical and radiographic features of aspiration pneumonia with early lung abscess formation, reflecting dysphagia-related aspiration of oropharyngeal flora including anaerobes. Amoxicillin-clavulanate provides broad cover against streptococci, Haemophilus influenzae and oral anaerobes, making it appropriate first-line therapy per Therapeutic Guidelines for aspiration pneumonia with suspected anaerobic involvement. Benzylpenicillin alone and ceftriaxone alone lack reliable anaerobic coverage. Doxycycline alone is inadequate for a patient with hypoxaemia and systemic sepsis requiring intravenous therapy. Vancomycin targets Gram-positive organisms including MRSA but does not cover the anaerobic and Gram-negative organisms typically implicated in aspiration.

• A. Vancomycin covers Gram-positive organisms including MRSA but does not provide anaerobic or Gram-negative coverage needed here.
• C. Benzylpenicillin alone lacks reliable activity against anaerobes and Gram-negative organisms implicated in aspiration pneumonia.
• D. Oral doxycycline is inadequate monotherapy for a hypoxaemic, septic patient requiring intravenous treatment with anaerobic cover.
• E. Ceftriaxone alone has poor activity against anaerobic oral flora, which are important pathogens in aspiration pneumonia.

Oseltamivir is most effective when started within 48 hours of symptom onset, and this patient falls within that window at 30 hours. She has chronic obstructive pulmonary disease, a recognised risk factor for influenza complications, which makes antiviral treatment appropriate even though she does not require hospitalisation. Treatment decisions during a confirmed local outbreak can be made on clinical grounds without waiting for laboratory confirmation, since delaying therapy reduces its effectiveness. Parenteral zanamivir is reserved for specific circumstances such as severe illness or inability to tolerate oral or inhaled therapy, not routine outpatient management.

• A. Intravenous zanamivir is reserved for severe disease or inability to use oral or inhaled therapy, not routine community treatment.
• C. The effective treatment window for oseltamivir is within 48 hours of symptom onset, not 12 hours.
• D. Waiting for PCR confirmation during a confirmed outbreak delays treatment and reduces antiviral effectiveness; treatment should not be withheld.
• E. Hospital admission is not required for antiviral treatment; outpatients with risk factors for complications should also be treated.

This presentation of a prolonged paroxysmal cough with whoop and post-tussive vomiting in an adult with waning vaccine immunity is characteristic of pertussis. Nasopharyngeal PCR is the preferred diagnostic test for Bordetella pertussis, particularly within the first 2 to 3 weeks of cough onset, and pertussis is a notifiable disease in Australia requiring prompt reporting to public health authorities to enable contact tracing and outbreak control, especially given her occupational exposure to young children. Chest X-ray is not required unless pneumonia is suspected clinically. Amoxicillin has no role, as pertussis requires macrolide therapy such as azithromycin, and sputum culture is not useful for this fastidious organism.

• A. There is no clinical indication of pneumonia; chest X-ray is not the appropriate next step for suspected pertussis.
• B. Amoxicillin does not treat pertussis; macrolides such as azithromycin are the appropriate antibiotic class if treatment is indicated.
• C. Pertussis is a notifiable condition requiring public health action, particularly given her occupational exposure to children; it should not be dismissed without investigation.
• D. Bordetella pertussis is fastidious and does not grow reliably on routine sputum culture; PCR is the preferred diagnostic method.

This presentation is consistent with acute bronchitis, a usually self-limiting viral illness, given the absence of fever, normal vital signs, normal oxygen saturation and lack of focal chest signs such as crackles or dullness suggesting consolidation. Antibiotics do not improve outcomes in acute bronchitis in healthy adults and contribute to antimicrobial resistance, so Therapeutic Guidelines recommend symptomatic management and patient education about the expected duration of cough, which can last several weeks. A chest X-ray is unnecessary in the absence of features suggesting pneumonia, such as fever, tachypnoea or focal findings. Sputum culture is not useful in this self-limiting viral illness.

• A. Sputum culture has no role in the management of self-limiting acute bronchitis and should not guide antibiotic use here.
• B. Doxycycline is not indicated, as there is no clinical evidence of bacterial pneumonia requiring antibiotic therapy.
• C. Chest X-ray is unnecessary in the absence of fever, tachypnoea, hypoxaemia or focal chest signs suggesting pneumonia.
• D. Antibiotics are not indicated in acute bronchitis in an otherwise healthy adult without clinical features suggesting bacterial pneumonia.

The Australian Immunisation Handbook recommends that Aboriginal and Torres Strait Islander people aged 50 years and over receive both pneumococcal vaccination and annual influenza vaccination, reflecting their increased risk of invasive pneumococcal disease and influenza-related complications compared with the general population, in whom these vaccines are generally recommended from age 65 years. His type 2 diabetes is an additional independent indication for both vaccines regardless of age or ethnicity, as it falls under the medical risk condition category in the Handbook. Influenza vaccination should be given annually due to waning immunity and antigenic drift, while pneumococcal vaccination follows a specific schedule rather than annual dosing.

• A. He qualifies for pneumococcal vaccination now, both due to his Aboriginal status at age 50 and over and his diabetes as a medical risk condition.
• B. Influenza vaccination is recommended annually for Aboriginal and Torres Strait Islander people aged 50 and over and for people with diabetes, not only from age 65.
• C. He qualifies for both vaccines now due to his Aboriginal status and his diabetes, independent of reaching age 65.
• D. Influenza vaccination should be given annually due to waning immunity and changing circulating strains, not as a single lifetime dose.

In a patient from a high-TB-burden country with classic symptoms (chronic cough, night sweats, weight loss) and upper zone findings, active pulmonary tuberculosis must be excluded first. Chest X-ray looking for upper lobe infiltrates, cavitation or fibronodular change, combined with at least three sputum samples for AFB smear and mycobacterial culture, is the standard initial work-up recommended by Therapeutic Guidelines. Culture also allows drug susceptibility testing, which is essential given rising rates of drug resistance in the Asia-Pacific region. IGRA and Mantoux testing are used for latent infection, not for diagnosing active disease.

• A. IGRA detects immune sensitisation to TB antigens and cannot distinguish active from latent infection; it is not the initial test for suspected active disease.
• B. Malignancy is less likely given the systemic symptoms, country of origin and clinical picture, which are classic for TB.
• C. Bronchoscopy is reserved for cases where sputum cannot be obtained or diagnosis remains uncertain after initial non-invasive testing.
• E. CT chest may be used later for further characterisation but is not the first-line investigation when active TB is suspected clinically.

Haemoptysis combined with hoarseness (suggesting possible recurrent laryngeal nerve involvement) and digital clubbing in a heavy smoker over 60 years old are red flag features strongly suggestive of lung cancer. Australian guidelines recommend urgent chest X-ray as the initial investigation, with prompt referral to a respiratory physician or lung cancer service for further imaging and tissue diagnosis if the X-ray is abnormal or if clinical suspicion remains high despite a normal film. Delaying investigation with a watch-and-wait approach or symptomatic treatment risks a delayed cancer diagnosis and worse prognosis. Clubbing is a recognised paraneoplastic sign of lung malignancy, particularly non-small cell carcinoma.

• A. There is no wheeze or history suggesting asthma; this presentation requires exclusion of malignancy, not an empirical steroid trial.
• B. Watchful waiting is inappropriate given the combination of red flag symptoms and signs strongly suggesting malignancy; delay risks worse outcomes.
• C. Spirometry assesses airflow limitation but does not investigate the cause of haemoptysis, hoarseness or clubbing, and does not replace urgent imaging.
• E. There is no evidence of infection such as fever or purulent sputum; antibiotics would not address the underlying red flag symptoms and would delay diagnosis.

Squamous cell carcinoma of the lung is classically associated with humoral hypercalcaemia of malignancy, caused by tumour secretion of parathyroid hormone-related peptide (PTHrP). PTHrP binds PTH receptors in bone and kidney, increasing bone resorption and renal calcium reabsorption, which explains the elevated calcium with an appropriately suppressed native PTH level due to negative feedback. This mechanism occurs independently of bone metastases and is one of the most common paraneoplastic syndromes seen in lung cancer. Symptoms of hypercalcaemia including confusion, constipation and polyuria reflect the effects of elevated calcium on the central nervous system, gut and kidneys.

• A. Vitamin D-mediated hypercalcaemia is more typical of lymphoma and granulomatous disease, not squamous cell lung carcinoma.
• B. Osteolytic metastases can cause hypercalcaemia but would typically show evidence of skeletal lesions and this mechanism is less common than humoral PTHrP-mediated hypercalcaemia in squamous cell carcinoma.
• C. Ectopic ACTH secretion causes Cushing syndrome, classically linked with small cell carcinoma, not hypercalcaemia.
• D. Ectopic ADH secretion causes SIADH with hyponatraemia, classically associated with small cell carcinoma, not hypercalcaemia.

Superior vena cava obstruction from an underlying mediastinal mass is an oncological emergency that requires prompt imaging to define the anatomy and guide definitive treatment (radiotherapy, chemotherapy or stenting), alongside corticosteroids to reduce peritumoural oedema and airway compromise while tissue diagnosis is being obtained. Contrast CT chest is the investigation of choice to delineate the level and extent of venous obstruction and plan intervention. Delaying treatment risks airway compromise, cerebral oedema and cardiovascular collapse. Tissue diagnosis (bronchoscopy or biopsy) is still required but follows stabilisation and imaging, not before it.

• A. Biopsy is needed for histology but not before stabilisation and imaging in a patient with impending airway/vascular compromise.
• B. This presentation represents a medical emergency; outpatient review risks life-threatening deterioration.
• C. Outpatient management is inappropriate given the risk of airway compromise and rapid progression.
• D. Surgical lymph node dissection is not an emergency intervention for SVC obstruction and is rarely indicated.

Malignant mesothelioma typically presents decades after asbestos exposure, with a latency period of 20 to 40 years, as seen in this patient exposed in the late 1970s and early 1980s. The combination of nodular pleural thickening, a large blood-stained effusion and chest pain in a patient with a clear occupational asbestos history is characteristic. Diagnosis requires pleural biopsy (often via thoracoscopy) with immunohistochemistry, as cytology alone has low sensitivity. Australia has one of the highest incidence rates of mesothelioma worldwide due to historical asbestos use in building and shipping industries.

• A. Tuberculous effusions are usually lymphocytic and straw-coloured, not blood-stained, and lack the occupational history correlation.
• B. Empyema presents with fever and purulent fluid, not blood-stained fluid, and there is no history of preceding pneumonia.
• C. Pleural plaques are usually asymptomatic incidental findings and do not cause effusion or nodular thickening with pain.
• D. Possible but less likely given the strong occupational exposure history and nodular pleural thickening pattern typical of mesothelioma.

A superior sulcus (Pancoast) tumour arises at the lung apex and characteristically invades local structures including the brachial plexus (C8-T1 roots, causing arm pain and hand muscle wasting in an ulnar distribution) and the sympathetic chain, producing Horner syndrome (ptosis, miosis, anhidrosis). The combination of apical chest X-ray opacity, arm pain in a C8-T1 distribution and Horner syndrome in a smoker is classic for this presentation. Diagnosis requires CT chest and tissue biopsy, with MRI to assess local invasion for staging. Most Pancoast tumours are non-small cell lung cancers, usually squamous cell or adenocarcinoma.

• A. Subclavian aneurysm does not typically cause this combination of findings and apical opacity.
• B. Disc herniation does not explain the apical lung opacity or Horner syndrome.
• D. Breast metastasis to the brachial plexus does not account for the apical lung opacity; the clinical picture fits a primary lung tumour.
• E. Thoracic outlet syndrome does not cause an apical mass on chest X-ray or Horner syndrome.

Idiopathic pulmonary fibrosis presents with progressive dyspnoea and dry cough in older patients, with fine bibasal crackles and finger clubbing on examination. The HRCT pattern of basal and subpleural predominant reticulation, honeycombing and traction bronchiectasis without significant ground-glass opacity is diagnostic of a usual interstitial pneumonia (UIP) pattern, which in the absence of an identifiable cause (connective tissue disease, drug, occupational exposure) confirms idiopathic pulmonary fibrosis. This diagnosis can be made without lung biopsy when the HRCT pattern is classic. Early referral for antifibrotic therapy (pirfenidone or nintedanib) and lung transplant assessment is recommended.

• A. NSIP typically shows ground-glass opacities with lower lobe predominance and less honeycombing than seen in this classic UIP pattern.
• B. Hypersensitivity pneumonitis typically shows upper/mid-zone ground-glass change, mosaic attenuation and air trapping, and usually has an identifiable exposure history.
• C. Sarcoidosis-related fibrosis is usually upper lobe predominant with perilymphatic nodularity, unlike this basal subpleural pattern.
• D. Chronic eosinophilic pneumonia shows peripheral consolidation, not honeycombing and traction bronchiectasis.

Hypersensitivity pneumonitis (bird fancier's lung in this case) results from repeated inhalation of organic antigens, provoking a combined type III (immune complex-mediated) and type IV (cell-mediated, delayed) hypersensitivity response in the lung parenchyma and small airways. Symptoms characteristically worsen with exposure and improve away from the trigger, as described here with symptoms worsening in the aviary and improving on weekends away from home. HRCT findings of ground-glass opacity, centrilobular nodules and mosaic attenuation with air trapping reflect bronchiolocentric inflammation. Management involves antigen avoidance, which is essential, and corticosteroids in more severe or persistent cases.

• A. HP is immune-mediated, not due to direct cytotoxic particulate injury.
• B. Anti-citrullinated protein antibodies are associated with rheumatoid arthritis-related lung disease, not hypersensitivity pneumonitis.
• D. Non-caseating granulomas with necrosis describes neither HP pathology (non-necrotising granulomas may occur, but this does not describe the core immune mechanism) nor fit the exposure-related pattern described.
• E. Type I hypersensitivity causes immediate IgE-mediated reactions such as asthma or anaphylaxis, not the delayed granulomatous lung injury seen here.

Amiodarone pulmonary toxicity is a well-recognised adverse effect that typically develops after months of therapy and presents with progressive dyspnoea, dry cough and bibasal or diffuse interstitial infiltrates on imaging, sometimes with an upper zone predominance. The drug accumulates in lung tissue due to its high lipophilicity and long half-life, causing direct cytotoxic injury and phospholipidosis in alveolar macrophages and type II pneumocytes. Concurrent hepatotoxicity and thyroid dysfunction are also recognised amiodarone adverse effects, making mild transaminase elevation consistent with this diagnosis. Management involves stopping amiodarone and considering corticosteroids in moderate to severe cases.

• A. Warfarin is not associated with pulmonary fibrosis.
• B. Digoxin does not cause interstitial lung disease.
• D. Flecainide is not a recognised cause of pulmonary fibrosis.
• E. Metoprolol is not associated with pulmonary fibrosis.

This presentation is classic for Löfgren syndrome, an acute presentation of sarcoidosis comprising bilateral hilar lymphadenopathy on chest X-ray, erythema nodosum and polyarthralgia (often ankle involvement), frequently with fever. This corresponds to Scadding stage I sarcoidosis (bilateral hilar lymphadenopathy without parenchymal infiltrate). Hypercalcaemia occurs in sarcoidosis due to increased extrarenal conversion of vitamin D to its active form by activated macrophages within granulomas. Löfgren syndrome has an excellent prognosis with a high rate of spontaneous remission, and treatment is usually symptomatic with NSAIDs rather than corticosteroids.

• B. Rheumatoid arthritis does not cause bilateral hilar lymphadenopathy or erythema nodosum as a presenting feature.
• C. Hodgkin lymphoma does not typically present with erythema nodosum and this symmetric hilar lymphadenopathy pattern; hypercalcaemia in malignancy is due to PTHrP or bone metastases, not vitamin D activation.
• D. Lymphadenopathy in lymphoma is usually asymmetric and progressive, not this acute symmetric bilateral hilar pattern with erythema nodosum.
• E. TB does not typically cause erythema nodosum and bilateral symmetric hilar lymphadenopathy with this acute triad; it usually causes unilateral lymphadenopathy with systemic symptoms and risk factors.

This patient has clinical features of tension pneumothorax: hypotension, tracheal deviation away from the affected side, hyperresonance, absent breath sounds, and distended neck veins. Tension pneumothorax is a clinical diagnosis requiring immediate decompression and must not be delayed for imaging. Needle decompression with a large-bore cannula in the second intercostal space, midclavicular line, converts the tension pneumothorax to a simple pneumothorax and is life-saving. Definitive management with an intercostal catheter follows once the tension physiology is relieved.

• A. Formal intercostal catheter placement takes longer to set up than needle decompression and is the next step after decompression, not the first step.
• B. Fluid resuscitation does not address the underlying mechanical obstruction to venous return and ventilation.
• C. Imaging delays life-saving treatment in a clinically obvious tension pneumothorax.
• E. Blood gas analysis does not alter the immediate need for decompression and wastes critical time.

Light's criteria classify pleural fluid as an exudate if any one of the following is present: pleural fluid/serum protein ratio greater than 0.5, pleural fluid/serum LDH ratio greater than 0.6, or pleural fluid LDH greater than two-thirds the upper limit of normal serum LDH. Here, the protein ratio is 48/68 = 0.71, which exceeds 0.5, meeting criteria for exudate. The LDH ratio is 220/180 = 1.22, also exceeding 0.6, reinforcing the exudate classification. Exudative effusions point towards causes such as malignancy, infection, or pulmonary embolism rather than heart failure.

• A. An absolute LDH value below 1000 U/L is not part of Light's criteria; the relevant comparison is the pleural/serum LDH ratio.
• B. Light's criteria use the pleural/serum LDH ratio, not a comparison with the normal serum LDH range, as the primary rule.
• D. The protein and LDH ratios both meet exudate criteria, excluding a transudate from cardiac failure.
• E. The calculated ratios already satisfy exudate criteria, so diuresis and repeat sampling are unnecessary.

The low pH (less than 7.2), low glucose, turbid appearance, and positive Gram stain confirm empyema, which is complicated by bacterial invasion of the pleural space rather than simple parapneumonic effusion. Empyema requires prompt drainage via an intercostal catheter in addition to intravenous antibiotics, as antibiotics alone cannot adequately penetrate loculated infected fluid. Delayed or inadequate drainage increases the risk of pleural thickening, fibrothorax, and the need for surgical decortication. Therapeutic Guidelines recommend early chest tube drainage guided by fluid characteristics such as pH, glucose and microbiology.

• A. Oral antibiotics are inadequate for a confirmed empyema with worsening sepsis and require escalation to intravenous therapy and drainage.
• B. Antibiotics alone without drainage fail to address the infected pleural collection and risk progression to a fibrothorax.
• C. Repeat aspiration alone delays definitive drainage and risks further loculation of infected fluid.
• E. Corticosteroids have no established role in empyema and do not address the need for source control.

This patient has a massive (high-risk) pulmonary embolism, defined by sustained hypotension despite fluid resuscitation in the setting of confirmed PE with right ventricular strain. Systemic thrombolysis with a thrombolytic agent such as alteplase is indicated in this setting, as it rapidly reduces clot burden and right ventricular pressure, improving survival, and she has no absolute contraindications described. Anticoagulation alone does not act quickly enough to reverse the haemodynamic compromise caused by the large clot burden. Surgical or catheter-directed embolectomy is reserved for patients with contraindications to thrombolysis or when thrombolysis fails.

• A. Surgical embolectomy is reserved for patients with contraindications to thrombolysis or failed thrombolysis, not as first-line therapy.
• B. Heparin alone does not rapidly reduce clot burden and is insufficient in the presence of haemodynamic instability.
• C. An IVC filter alone prevents further embolisation but does not treat the existing large clot burden causing shock.
• E. Oral anticoagulants have delayed onset and are not appropriate in haemodynamically unstable PE.

A loud, palpable pulmonary second heart sound and a parasternal heave reflect increased right ventricular pressure and are the most specific clinical signs of pulmonary hypertension among the findings given. Right ventricular hypertrophy from chronic pressure overload produces the heave, while increased force of pulmonary valve closure produces the loud P2. Ankle oedema, raised jugular venous pressure, and hypoxaemia are features of right heart failure or the underlying lung disease but are less specific to pulmonary hypertension itself. Confirmation requires echocardiography estimating pulmonary artery pressure, with right heart catheterisation as the diagnostic gold standard.

• A. Raised jugular venous pressure alone reflects elevated right atrial pressure but is less specific than the cardiac examination findings of right ventricular pressure overload.
• B. Ankle oedema reflects right heart failure from any cause and is not specific to pulmonary hypertension.
• D. Fine inspiratory crackles reflect parenchymal lung disease, not pulmonary hypertension specifically.
• E. Hypoxaemia is common in chronic lung disease generally and is not specific for pulmonary hypertension.

A STOP-BANG score of 5 to 8 indicates high risk of moderate to severe obstructive sleep apnoea, warranting objective testing. Polysomnography remains the gold standard investigation to confirm the diagnosis, determine severity using the apnoea-hypopnoea index, and guide management, including eligibility for continuous positive airway pressure therapy. Given his occupation as a truck driver, confirming and treating OSA is also important for road safety and fitness-to-drive assessment. Empirical treatment without a confirmed diagnosis is not appropriate, as it does not establish severity or guide monitoring.

• A. A high STOP-BANG score indicates a need for formal testing rather than attributing symptoms to obesity without objective confirmation.
• B. Stimulant medication does not address the underlying obstructive sleep apnoea and is not first-line management.
• C. CPAP should not be commenced empirically without a confirmed diagnosis and severity assessment from a sleep study.
• E. A high-risk screening score in a commercial driver warrants prompt objective testing rather than delayed review.

This patient has severe obstructive sleep apnoea (AHI greater than 30 events per hour) with significant daytime sleepiness and desaturation, and he holds a safety-critical occupation. CPAP is the first-line treatment for moderate to severe OSA because it most reliably normalises the AHI and reduces daytime sleepiness, which is essential for his fitness to drive. Mandibular advancement splints are reserved for mild to moderate OSA or for patients who cannot tolerate CPAP. Weight loss is recommended as an adjunct but takes months and will not rapidly address his current driving risk. Surgery is not first-line therapy.

• A. Upper airway surgery is not a first-line option and is reserved for select cases unresponsive to other measures.
• B. Weight loss is a useful adjunct but too slow to address his current severe OSA and occupational safety risk.
• C. Mandibular advancement splints are appropriate for mild-moderate OSA, not severe disease with marked desaturation.
• E. Positional therapy is only effective for positional OSA, not generalised severe disease with this AHI.

Under the Austroads 'Assessing Fitness to Drive' standards, a commercial vehicle driver with severe OSA and symptomatic excessive sleepiness (such as episodes of falling asleep while stopped) is required to cease driving until the condition is effectively treated and stability is demonstrated. The treating doctor has a professional and often legal obligation to advise the patient not to drive and to notify the driver licensing authority, particularly for commercial licence holders where the standards are stricter. Simply reviewing later or trusting self-restriction does not meet the safety threshold given his reported sleep episodes. CPAP may later allow return to driving, but only after demonstrated compliance and symptom resolution confirmed by follow-up, not immediately upon starting therapy.

• A. A driving simulator assessment is not part of the standard pathway and delays the required immediate restriction.
• B. Self-restriction is not an accepted substitute for formal medical clearance in commercial driving standards.
• C. Continuing to drive unrestricted for three months is unsafe given his reported sleep episodes and commercial licence status.
• D. Return to driving requires demonstrated treatment compliance and symptom control, not simply starting CPAP.

This infant has clinical bronchiolitis with mild disease: saturations above 92%, mild work of breathing, and adequate oral intake. Therapeutic Guidelines recommend supportive care only, as bronchiolitis is a viral illness (usually RSV) with no proven benefit from bronchodilators, corticosteroids, antibiotics or hypertonic saline. Management centres on maintaining hydration, monitoring for deterioration, and clear safety-net advice for parents regarding increased work of breathing, reduced feeding or apnoeic episodes. Routine chest X-ray is not indicated as it does not change management in typical bronchiolitis and may lead to inappropriate antibiotic use.

• B. Nebulised adrenaline is used for croup, not bronchiolitis, and hospital observation is unnecessary for mild disease.
• C. Antibiotics are not indicated because bronchiolitis is viral and there is no evidence of bacterial superinfection.
• D. Chest X-ray and hypertonic saline are not indicated in typical mild bronchiolitis and do not alter management.
• E. Bronchodilators and corticosteroids have no proven benefit in bronchiolitis and are not recommended.

This child has moderate croup, with stridor at rest and recession but no cyanosis, severe distress or altered conscious state. Therapeutic Guidelines recommend a single dose of oral dexamethasone 0.15 mg/kg (or up to 0.6 mg/kg where only higher-strength formulations are available) for croup of this severity, as a single dose reduces symptom duration and hospital re-presentation without need for repeated dosing. Nebulised adrenaline is reserved for severe croup with marked distress or impending respiratory failure, used alongside steroids rather than instead of them. Prolonged courses of oral prednisolone are not standard for croup, which is a self-limiting viral illness typically requiring only a single steroid dose.

• B. Nebulised adrenaline is reserved for severe croup and should be combined with, not substituted for, corticosteroid treatment.
• C. Nebulised budesonide is an alternative when the oral route is not tolerated, but oral dexamethasone is preferred and a dose should still be given.
• D. Repeated daily dosing of dexamethasone is not required for croup, which typically resolves after a single dose.
• E. A 5-day course of prednisolone is unnecessary for croup, which responds to a single steroid dose.

This presentation, with drooling, tripod positioning, muffled voice and stridor in an unvaccinated child, is classic for acute epiglottitis, a life-threatening emergency caused by airway obstruction from a swollen epiglottis, most often due to Haemophilus influenzae type b. The priority is to avoid any intervention that may precipitate complete airway obstruction, including oropharyngeal examination, cannulation, X-rays or unnecessary handling. The child should be kept calm, ideally with a parent, while senior anaesthetic and ENT staff are urgently called to secure the airway under controlled conditions, usually in an operating theatre. Nebulised adrenaline is used for croup, not epiglottitis, and delaying airway management to trial it is unsafe.

• B. Attempting cannulation before securing the airway can distress the child and precipitate obstruction; airway takes priority.
• C. Oropharyngeal examination can precipitate complete airway obstruction and must be avoided in suspected epiglottitis.
• D. Nebulised adrenaline is not effective for epiglottitis, and delaying definitive airway management is dangerous.
• E. Neck X-ray delays definitive airway management and risks worsening obstruction if the child becomes distressed.

Young children typically cannot generate the inspiratory flow required for dry powder or breath-actuated devices, and cannot reliably coordinate actuation with inhalation for a metered-dose inhaler used alone. Therapeutic Guidelines and Australian asthma management guidelines recommend a pressurised metered-dose inhaler used with a spacer, with a facemask for younger children or a mouthpiece once they can seal their lips around it, as this ensures effective drug delivery regardless of coordination or inspiratory effort. Spacers also reduce oropharyngeal deposition and systemic absorption. Dry powder and breath-actuated devices are generally only suitable from around 6 to 8 years of age once adequate inspiratory flow is reliably achieved.

• A. A metered-dose inhaler without a spacer requires coordination that young children lack, leading to poor drug delivery.
• B. Soft mist inhalers used without a spacer require coordination that is unreliable in preschool-aged children.
• C. Dry powder inhalers require inspiratory flow that preschool children generally cannot generate reliably.
• E. Breath-actuated inhalers still require adequate inspiratory flow, which this age group cannot reliably produce.

This infant's presentation, including an elevated immunoreactive trypsinogen on newborn screening, two CFTR variants, a history of meconium ileus, and failure to thrive with steatorrhoea from pancreatic insufficiency, is highly suggestive of cystic fibrosis. The sweat chloride test remains the diagnostic gold standard, with a chloride concentration of 60 mmol/L or greater on two occasions confirming the diagnosis in conjunction with the clinical picture and genetic findings. Faecal elastase is useful for assessing pancreatic exocrine function but does not establish the diagnosis of cystic fibrosis itself. Newborn screening with immunoreactive trypsinogen and genetic testing identifies infants at risk, but sweat chloride testing is required for definitive diagnostic confirmation.

• A. Faecal elastase assesses pancreatic exocrine function but is not the diagnostic test for cystic fibrosis.
• B. Abdominal ultrasound may show bowel changes from meconium ileus but does not confirm the underlying diagnosis.
• C. Repeating the trypsinogen level does not add diagnostic value once screening has already been positive with CFTR variants identified.
• D. Stool microscopy for parasites is irrelevant to this presentation and does not investigate the suspected diagnosis.

Chronic wet cough lasting more than 4 weeks that fails to resolve with antibiotics is the hallmark of protracted bacterial bronchitis or early bronchiectasis, and Aboriginal and Torres Strait Islander children in remote communities have a markedly higher incidence of bronchiectasis than other Australian children. Early referral for HRCT chest and specialist assessment is critical because early diagnosis and treatment can prevent progression to irreversible lung damage. Delayed recognition is a major contributor to the disproportionate burden of chronic lung disease seen in this population as adults. Sweat chloride testing may be part of the work-up but does not replace imaging and specialist referral. Empirical inhaled corticosteroids or prolonged antibiotics without a diagnosis risk missing the underlying structural lung disease.

• A. Sweat chloride testing alone is insufficient; it does not assess for bronchiectasis and should not replace imaging and referral.
• B. Antibiotics alone without imaging or specialist input will not identify or address underlying structural airway damage.
• D. Chronic wet cough beyond 4 weeks is not normal and warrants active investigation, especially in this high-risk population.
• E. There is no wheeze or evidence of reversible airway obstruction described, making asthma an unlikely primary diagnosis.

Aboriginal and Torres Strait Islander adults have a substantially higher burden of invasive pneumococcal disease and are recommended to start pneumococcal vaccination from age 50, earlier than the general population schedule starting at 70. The recommended schedule for medical risk groups, which includes Aboriginal and Torres Strait Islander adults aged 50 years and over, is 13-valent conjugate vaccine followed by 23-valent polysaccharide vaccine at least 2 months later, with a second dose of 23-valent polysaccharide vaccine given 5 years after the first. This conjugate-then-polysaccharide sequence improves immunogenicity compared with polysaccharide vaccine alone. Diabetes further adds to his risk, reinforcing the need for the full schedule rather than a single dose.

• A. This follows the general population schedule starting at 70 years, which does not apply given his higher risk and eligibility from age 50.
• B. Conjugate vaccine alone is insufficient; polysaccharide vaccine is also required to broaden serotype coverage.
• D. A single 23-valent dose alone, without prior conjugate vaccine and a booster at 5 years, does not meet the recommended schedule for this risk group.
• E. Waiting until age 70 ignores the recommendation to begin vaccination from age 50 in this higher-risk population.

Aboriginal and Torres Strait Islander children living in remote and rural areas have among the highest rates of acute rheumatic fever and rheumatic heart disease in the world, and a new murmur in a child with recurrent respiratory tract infections should prompt echocardiographic assessment even while a concurrent chest infection is being treated. Echocardiography is the key investigation to confirm or exclude valvular involvement consistent with rheumatic heart disease. Treating the pneumonia is appropriate but must not delay cardiac assessment given the high background prevalence and the serious long-term consequences of missed rheumatic heart disease. Secondary prophylaxis should only begin once rheumatic fever or rheumatic heart disease is confirmed, and invasive cardiac catheterisation is not an appropriate initial investigation.

• A. Deferring cardiac assessment until heart failure develops risks missing early, treatable rheumatic heart disease.
• B. Cardiac catheterisation is invasive and not indicated as an initial investigation; echocardiography is the appropriate first test.
• C. Secondary prophylaxis should not be started until the diagnosis is confirmed by echocardiography and clinical criteria.
• E. Given the high regional prevalence of rheumatic heart disease, a new murmur in this context should not be dismissed as innocent without assessment.

Type 2 respiratory failure is defined by hypoxaemia (PaO2 below 60 mmHg) together with hypercapnia (PaCO2 above 45 mmHg), both of which are present here. The low pH of 7.28 confirms acute decompensation, while the elevated bicarbonate of 30 mmol/L reflects renal compensation for a degree of chronic hypercapnia, indicating an acute-on-chronic respiratory acidosis typical of an infective COPD exacerbation. If this were purely chronic and compensated, the pH would be closer to normal despite the elevated CO2. Type 1 respiratory failure refers to hypoxaemia with a normal or low PaCO2, which does not apply here given the markedly elevated PaCO2.

• A. PaCO2 is markedly elevated, not low, so this is type 2 not type 1 failure, and the pH is acidotic not alkalotic.
• B. The primary disturbance is respiratory, driven by CO2 retention, not a primary metabolic acidosis.
• D. Type 1 failure requires a normal or low PaCO2; here the PaCO2 is elevated, and the primary disturbance is acidosis, not alkalosis.
• E. The abnormal pH indicates the compensation is incomplete; gas exchange is clearly abnormal given the hypoxaemia and hypercapnia.

Persistent respiratory acidosis with pH less than 7.35 and hypercapnia despite optimal medical therapy, including bronchodilators and corticosteroids, is a key indication for non-invasive ventilation in an acute COPD exacerbation. Non-invasive ventilation reduces the work of breathing, improves alveolar ventilation, and lowers the need for intubation and associated complications in patients who remain alert and can protect their airway. Invasive ventilation is reserved for those who fail non-invasive ventilation, cannot tolerate it, or have a reduced conscious state or inability to protect the airway. Increasing oxygen without addressing the ventilatory failure risks worsening hypercapnia by removing the hypoxic respiratory drive.

• A. Discharge is inappropriate given ongoing acute respiratory acidosis and hypoxaemia despite maximal medical therapy.
• B. Over-oxygenation in COPD can worsen hypercapnia by blunting hypoxic respiratory drive and increasing ventilation-perfusion mismatch.
• C. Aminophylline is not first-line and delaying ventilatory support risks further deterioration given the current acidosis.
• E. Invasive ventilation is reserved for patients who fail or cannot tolerate non-invasive ventilation or who cannot protect their airway, neither of which applies here.

The Berlin definition of acute respiratory distress syndrome requires onset within 1 week of a known clinical insult, bilateral opacities on chest imaging not fully explained by cardiac failure or fluid overload, and a PaO2/FiO2 ratio of 300 mmHg or less with a minimum positive end-expiratory pressure of 5 cmH2O. This patient's PaO2/FiO2 ratio is 54/0.6, which equals 90 mmHg, meeting criteria for severe ARDS, in the setting of a clear precipitating illness, sepsis from pyelonephritis, with a normal echocardiogram excluding a primary cardiac cause. Ventilator-associated pneumonia and pulmonary embolism do not typically produce bilateral diffuse opacities with this pattern so early in the clinical course, and there is no history of recent transfusion to suggest transfusion-related acute lung injury.

• B. There is no clinical evidence of embolism such as pleuritic pain or risk factors, and infarction would not typically cause bilateral diffuse opacities.
• C. There is no history of recent blood product transfusion, which is required to diagnose transfusion-related acute lung injury.
• D. Ventilator-associated pneumonia typically develops after at least 48 hours of ventilation and usually causes focal rather than diffuse bilateral opacities.
• E. Normal left ventricular function on echocardiogram and the clinical context of sepsis argue against a cardiogenic cause.

The 5As framework, Ask, Advise, Assess, Assist, Arrange, as recommended in the RACGP Red Book, directs clinicians to ask about smoking status, then advise clearly and personally on the benefits of quitting regardless of current readiness to change, and then assess the patient's willingness to quit before moving to assist or arrange follow-up. Brief, clear, personalised advice from a general practitioner increases quit attempts even in patients who are not currently contemplating quitting. Arranging referral or prescribing nicotine replacement therapy before assessing readiness skips essential steps in the framework. Avoiding the topic entirely misses an opportunity for brief intervention, which should occur opportunistically rather than requiring a dedicated appointment.

• A. Brief opportunistic advice should still be given even if the patient initially states low interest, as it increases future quit attempts.
• B. Nicotine replacement therapy should be offered after assessing readiness and interest in quitting, not initiated immediately without discussion.
• D. Brief intervention using the 5As can and should occur opportunistically during the current consultation rather than requiring a separate appointment.
• E. Referral should follow assessment of readiness and patient preference, not precede advice and assessment.

Current spirometry quality standards require that the forced vital capacity and forced expiratory volume in 1 second from the two best acceptable curves agree within 150 mL (or within 100 mL for people with a forced vital capacity under 1 litre) to be considered repeatable. A difference of 250 mL between the best two curves exceeds this threshold and indicates poor repeatability, so the test should be repeated or interpreted with caution. A clear end-expiratory plateau and expiratory time of at least 3 to 6 seconds are markers of good individual curve quality, but they do not substitute for between-curve repeatability. Only three technically acceptable curves are generally required if repeatability criteria are met; up to eight may be attempted if needed, but five is not an absolute fixed requirement.

• A. Expiratory time requirements are a guide for adequacy of a single curve, not an absolute cut-off that alone invalidates an otherwise plateaued curve.
• C. 250 mL variation exceeds the accepted repeatability threshold of 150 mL (or 100 mL for very low volumes), so this does not meet standard criteria.
• D. Three acceptable curves meeting repeatability criteria are sufficient; five curves are not an absolute requirement if criteria are met with fewer attempts.
• E. An end-expiratory plateau is an important marker of complete exhalation and is relevant to assessing individual curve quality.

The baseline FEV1/FVC ratio of 0.66 confirms airflow obstruction. The post-bronchodilator increase in FEV1 from 2.10 L to 2.55 L represents a rise of 21% from baseline and 450 mL in absolute terms, exceeding the threshold of ≥12% and ≥200 mL used to define significant reversibility. This degree of reversible obstruction in a patient with a compatible clinical history (episodic wheeze, nocturnal cough) is diagnostic of asthma. COPD typically shows irreversible or only partially reversible obstruction.

• A. Restrictive disease shows a reduced FVC with a normal or increased FEV1/FVC ratio, not reduced ratio as seen here.
• B. COPD obstruction is usually fixed or only minimally reversible, unlike the large bronchodilator response seen here.
• C. The reduced FEV1/FVC ratio confirms obstruction, so spirometry is not normal.
• D. Vocal cord dysfunction classically causes a flattened inspiratory loop with normal spirometry between episodes, not reversible obstruction.

Budesonide-formoterol is the only combination approved and recommended for SMART because formoterol has a rapid onset of action (within minutes) comparable to salbutamol, in addition to its long duration of action. This allows the same inhaler to be used both for daily maintenance dosing and for symptom relief, reducing reliance on short-acting beta agonists and lowering exacerbation risk. Salmeterol has a slow onset of action, making it unsuitable as a reliever despite being a long-acting beta agonist. Australian guidelines (eTG, National Asthma Council) specifically endorse budesonide-formoterol for this purpose.

• A. Salmeterol has a slow onset of action (15-20 minutes) and cannot be used as a reliever medication.
• B. Vilanterol is a once-daily long-acting beta agonist with slow onset, not suitable for as-needed relief.
• D. Tiotropium-olodaterol is a long-acting muscarinic antagonist/LABA combination used in COPD, not a SMART reliever option.
• E. Salbutamol combined with an ICS in a fixed inhaler is not how SMART is formulated; SMART uses an ICS/formoterol combination given flexibly.

A silent chest indicates minimal air movement due to near-complete airway closure, and a normal or rising PaCO2 (here 58 mmHg) signals respiratory muscle fatigue and impending respiratory failure, both classic markers of life-threatening asthma. Bradycardia, bradypnoea, drowsiness and hypotension in this context are additional ominous signs of exhaustion and hypoxaemia. Features such as tachypnoea, tachycardia and inability to complete sentences indicate severe but not necessarily life-threatening asthma. Peak flow 50-75% of predicted is consistent with a mild-to-moderate attack.

• A. Inability to complete sentences in one breath is a feature of severe asthma.
• B. Tachycardia above 110/min is a feature of severe, not life-threatening, asthma.
• D. A peak flow of 50-75% predicted indicates a mild to moderate attack, not life-threatening disease.
• E. Tachypnoea above 25/min is a feature of severe, not life-threatening, asthma.

A clinically significant bronchodilator response requires an increase in FEV1 of at least 12% from baseline AND at least 200 mL in absolute terms. Here the rise is 120 mL, which is only 5% of the baseline FEV1 of 2.40 L, so neither threshold is met and the result does not support a diagnosis of reversible airway obstruction on this test. Normalisation of the FEV1/FVC ratio is not a required criterion for defining reversibility. A trivial rise of any magnitude is not diagnostic; the defined percentage and absolute thresholds must both be met.

• A. Normalisation of the ratio to above 0.80 is not part of the standard reversibility criterion.
• B. Reversibility requires meeting defined percentage and absolute thresholds, not merely any increase in FEV1.
• D. The correct percentage threshold is 12% of the baseline FEV1, not 10% of predicted FEV1, and this response does not meet even that figure.
• E. An absolute rise must also meet the 200 mL threshold and be at least 12% of baseline; 120 mL alone is insufficient and below both thresholds.

Short-acting beta agonists such as salbutamol are highly effective at preventing exercise-induced bronchoconstriction when taken 10-15 minutes before exercise, providing protection for 2-3 hours through bronchodilation and prevention of mediator release from airway mast cells. Taking salbutamol after exercise treats symptoms rather than preventing them. Doubling the inhaled corticosteroid dose on training days is not supported by guidelines and does not address the acute bronchoconstrictive response to exercise. A warm-up alone may reduce symptoms in some patients but is not as reliably effective as pre-exercise salbutamol for someone with confirmed symptoms.

• A. Montelukast can be used preventively but is not first-line, and using it only on competition days is inconsistent with its recommended regular or pre-exercise dosing timing.
• C. A warm-up alone is a reasonable adjunct but does not reliably prevent symptoms in patients with confirmed exercise-induced bronchoconstriction without pre-treatment.
• D. Doubling the daily ICS dose on training days is not a recommended strategy for preventing exercise-induced bronchoconstriction.
• E. Giving salbutamol after exercise treats established symptoms rather than preventing the bronchoconstriction from occurring.

Inhaled corticosteroids, including budesonide, are considered safe throughout pregnancy and should be continued at the dose needed to maintain good asthma control. Poorly controlled asthma is associated with significant risks including pre-eclampsia, intrauterine growth restriction, preterm birth and increased perinatal mortality, which outweigh any theoretical risk from inhaled corticosteroid use. Stopping or reducing the preventer dose risks loss of control and exacerbations, which are more dangerous to the fetus than continued treatment. Leukotriene receptor antagonists are not first-line preventers in pregnancy and inhaled corticosteroids remain the preferred option.

• A. Reducing the dose without clinical indication risks under-treatment and loss of asthma control.
• B. Stopping the ICS risks loss of asthma control, increasing the risk of exacerbations which are more harmful to the fetus than the medication itself.
• D. Stopping all medication exposes both mother and fetus to the risks of uncontrolled asthma, including hypoxia and exacerbation-related complications.
• E. Leukotriene receptor antagonists are not first-line preventers in pregnancy; inhaled corticosteroids remain preferred.

The pattern of symptomatic improvement during days or periods away from work (such as weekends or holidays) with recurrence upon return to the workplace is the key diagnostic clue for occupational asthma, reflecting a causal relationship with a workplace sensitiser or irritant, in this case likely isocyanates used in spray paint. This temporal relationship should prompt further objective assessment, such as serial peak flow monitoring at and away from work, and specialist referral. Onset timing alone, absence of atopy, or the specific time of day symptoms worsen are less discriminating features than the work-related periodicity.

• A. Timing within the shift is less specific than the overall pattern of improvement away from work and recurrence on return.
• B. Absence of atopy makes a new workplace sensitiser more likely as a cause, but this alone does not establish the diagnosis.
• C. The specific duration since symptom onset does not by itself establish an occupational cause.
• D. Physical demands of a job are not relevant to the diagnosis of occupational asthma from chemical or sensitiser exposure.

For patients with persistent breathlessness on short-acting bronchodilators alone and no history of frequent exacerbations, Therapeutic Guidelines recommend starting regular long-acting bronchodilator monotherapy, with a long-acting muscarinic antagonist (LAMA) or long-acting beta-agonist (LABA) being first-line. Inhaled corticosteroids are reserved for patients with frequent exacerbations or features of asthma overlap, as they increase pneumonia risk without clear benefit in low-exacerbation-risk COPD. Dual bronchodilator therapy (LAMA/LABA) is generally reserved for patients with ongoing symptoms despite single long-acting bronchodilator therapy. Theophylline is a later option due to its narrow therapeutic index and side-effect profile.

• A. Dual bronchodilator therapy is typically introduced after inadequate response to a single long-acting bronchodilator, not as the first step.
• B. ICS/LABA combinations are reserved for exacerbation-prone or overlap phenotypes, not the initial step for symptom control alone.
• C. Inhaled corticosteroids are not first-line and are reserved for patients with frequent exacerbations or asthma features, which this patient lacks.
• E. Theophylline is a later-line option due to its narrow therapeutic index and is not appropriate as an early addition.

In patients with chronic hypercapnic COPD, high-flow oxygen can precipitate worsening hypercapnia through several mechanisms: blunting of hypoxic respiratory drive (which has become the dominant stimulus to breathe in chronic CO2 retainers), release of hypoxic pulmonary vasoconstriction leading to increased perfusion of poorly ventilated alveoli (worsening V/Q mismatch), and the Haldane effect, where oxyhaemoglobin has a reduced affinity for carbon dioxide, releasing more CO2 into the plasma. This combination leads to rising PaCO2, respiratory acidosis, and CO2 narcosis, explaining his drowsiness. Target oxygen saturation in COPD exacerbations should typically be 88 to 92% using titrated low-flow oxygen.

• A. Oxygen causes pulmonary vasodilation, not rebound vasoconstriction, and this is not the primary mechanism of CO2 retention.
• B. Hyperoxia does not directly suppress the respiratory centre at the doses used clinically; the mechanism relates to loss of hypoxic drive and V/Q mismatch.
• C. Oxygen therapy does not cause bronchospasm; this is not the mechanism of oxygen-induced hypercapnia.
• E. Surfactant dysfunction from oxygen toxicity occurs with prolonged high-concentration exposure over days, not within 30 minutes, and is not the mechanism here.

Long-term oxygen therapy (LTOT) is indicated in stable COPD patients with a PaO2 consistently at or below 55 mmHg (7.3 kPa) on room air, confirmed on two measurements taken at least 3 weeks apart while clinically stable. This patient meets that threshold on both occasions, and LTOT has been shown to improve survival in such patients when used for at least 15 hours a day. The presence of cor pulmonale or polycythaemia lowers the threshold to PaO2 56 to 59 mmHg (7.3 to 8.0 kPa), but is not required when PaO2 is already at or below 55 mmHg. Overnight oximetry and exercise-only oxygen are relevant to nocturnal or exertional desaturation assessment, not to qualification for continuous LTOT in this setting.

• A. A PaO2 at or below 55 mmHg on two stable measurements meets the threshold for long-term oxygen therapy and should not simply be reassured.
• B. Delaying further assessment for 12 months is inappropriate when the patient already meets confirmed criteria for long-term oxygen therapy.
• D. Ambulatory or nocturnal-only oxygen is for patients who desaturate only with exertion or sleep, not for this patient who meets criteria for continuous LTOT.
• E. Overnight oximetry assesses nocturnal desaturation and is not required before referral when daytime PaO2 already meets LTOT criteria.

Pulmonary rehabilitation is a structured program combining supervised exercise training, education, and self-management support, and is strongly recommended for patients with COPD who have persistent breathlessness or functional limitation, particularly following a recent exacerbation and hospitalisation. It has high-quality evidence for improving exercise capacity, reducing symptoms, improving quality of life, and reducing readmission rates when started soon after an exacerbation. This patient's functional limitation and deconditioning without evidence of hypoxaemia or severe structural disease make her an ideal candidate. Oxygen therapy, surgical referral, and increasing ICS dose are not supported by her current clinical picture.

• A. Lung volume reduction surgery is reserved for selected patients with severe hyperinflation and specific emphysema patterns after optimisation of medical therapy, not as a next step here.
• B. There is no indication her current exacerbation or symptoms are due to inadequate inhaled corticosteroid dosing; her issue is functional deconditioning.
• D. Rest worsens deconditioning in COPD; graded exercise through pulmonary rehabilitation is the recommended approach.
• E. There is no stated evidence of resting hypoxaemia meeting criteria for long-term oxygen therapy in this patient.

Early-onset emphysema in a non-smoker, especially with a basal/lower lobe predominant panacinar pattern on CT and a family history of unexplained liver disease, should raise suspicion for alpha-1 antitrypsin deficiency. This autosomal codominant condition results in reduced circulating levels of alpha-1 antitrypsin, a protease inhibitor that normally protects lung tissue from neutrophil elastase, leading to early emphysema; the same abnormal protein can accumulate in hepatocytes causing liver disease. A low serum alpha-1 antitrypsin level prompts confirmatory genotyping or phenotyping. The other investigations are not indicated by this clinical and radiological picture.

• A. Serum IgE is used in the assessment of allergic bronchopulmonary aspergillosis or atopy, not in the evaluation of early-onset emphysema.
• C. Allergy testing is relevant to asthma or atopic disease, not to this presentation of early emphysema with family history of liver disease.
• D. Sweat chloride testing is used to diagnose cystic fibrosis, which typically presents with bronchiectasis and recurrent infections rather than isolated panacinar emphysema in an adult.
• E. Repeating imaging without addressing the underlying cause would delay diagnosis when a specific and simple blood test is indicated.